Roy Winston
CIK 1751757 · Chief Medical Officer · last filed 2023-08-04
Roy Winston is a Chief Medical Officer who has filed 18 SEC Form 4 insider transactions across 1 company since 2019. The most recent filing, for PCRX, was dated Nov 13, 2023. Across all open-market trades the lifetime net is −$3.2M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.9M across reported positions. 19 SEC filings were submitted jointly with Pacira BioSciences, Inc.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
PCRX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
5401 WEST KENNEDY BOULEVARD, SUITE 890
TAMPA, FL 33609
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PCRX | Chief Medical Officer | 52,440 | $36.45 | $1.91M | -$3.22M | 14 | 2023-08-04 |
Recent Filings
18 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-11-13 | PCRX | Notice (144) | −31,000 | -$875.9K | EDGAR |
| 2023-08-04 | PCRX | Sell (S) | −509 | -$17.8K | EDGAR |
| 2023-08-02 | PCRX | Notice (144) | −509 | -$17.8K | EDGAR |
| 2023-06-16 | PCRX | Grant (A) | +10,950 | $0 | EDGAR |
| 2023-06-07 | PCRX | Notice (144) | −1,857 | -$70.3K | EDGAR |
| 2023-06-07 | PCRX | Sell (S) | −3,636 | -$139.7K | EDGAR |
| 2023-06-06 | PCRX | Notice (144) | −1,779 | -$69.4K | EDGAR |
| 2022-08-05 | PCRX | Sell (S) | −476 | -$26.5K | EDGAR |
| 2022-06-08 | PCRX | Mixed | −1,396 | -$862.3K | EDGAR |
| 2021-11-08 | PCRX | Exer (M) | +10,000 | $481.5K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.